BiotechTube

Roflumilast + Placebo

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation

Conditions

Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation

Trial Timeline

Feb 1, 2012 → Mar 1, 2014

NCT ID
NCT01473758

About Roflumilast + Placebo

Roflumilast + Placebo is a phase 2 stage product being developed by AstraZeneca for Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation. The current trial status is terminated. This product is registered under clinical trial identifier NCT01473758. Target conditions include Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation.

What happened to similar drugs?

20 of 20 similar drugs in Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation were approved

Approved (20) Terminated (3) Active (0)
✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved
✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved
✅placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirinDaiichi SankyoApproved
✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (10)

NCT IDPhaseStatus
NCT01509677Phase 3Completed
NCT01473758Phase 2Terminated
NCT01443845ApprovedCompleted
NCT01329029ApprovedCompleted
NCT00424268Phase 3Completed
NCT00313209Phase 3Completed
NCT00297115Phase 3Completed
NCT00297102Phase 3Completed
NCT00242320Phase 3Completed
NCT01365533Phase 2Completed

Competing Products

20 competing products in Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation

See all competitors
ProductCompanyStageHype Score
Levofloxacin 500Dr. Reddy's LaboratoriesPre-clinical
23
mRNA-0184ModernaPhase 1
0
Lubiprostone + Lubiprostone + PlaceboDr. Reddy's LaboratoriesPhase 3
37
macitentan 10 mgBML, Inc.Phase 3
32
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
29
TERN-701Terns PharmaceuticalsPhase 1/2
36
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
23
LY3556050 + PlaceboEli LillyPhase 2
35
THB001Third Harmonic BioPhase 1
11
BriquilimabJasper TherapeuticsPhase 1/2
26
BriquilimabJasper TherapeuticsPhase 1/2
14
BriquilimabJasper TherapeuticsPhase 2
29
Empagliflozin + Matching placeboEli LillyPhase 3
40
LY3461767 + PlaceboEli LillyPhase 1
29
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
44
LY3526318 + PlaceboEli LillyPhase 2
35
PirtobrutinibEli LillyPhase 2
42
Ibrutinib + LY3214996Eli LillyPhase 1
21
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
27
LYR-210Lyra TherapeuticsPhase 2
25